Display options
Cite
Teck AT, Urban S, Quass P, et al. Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivo. Cancer Immunol Immunother. 2021;70(10):3055doi: 10.1007/s00262-021-02977-6.
Teck, A. T., Urban, S., Quass, P., Nelde, A., Schuster, H., Letsch, A., Busse, A., Walz, J. S., Keilholz, U., & Ochsenreither, S. (2021). Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivo. Cancer immunology, immunotherapy : CII, 70(10), 3055. https://doi.org/10.1007/s00262-021-02977-6
Teck, Anja Tatjana, et al. "Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivo." Cancer immunology, immunotherapy : CII vol. 70,10 (2021): 3055. doi: https://doi.org/10.1007/s00262-021-02977-6
Teck AT, Urban S, Quass P, Nelde A, Schuster H, Letsch A, Busse A, Walz JS, Keilholz U, Ochsenreither S. Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivo. Cancer Immunol Immunother. 2021 Oct;70(10):3055. doi: 10.1007/s00262-021-02977-6. PMID: 34170381; PMCID: PMC8423697.
Copy Download .nbib Format: NLM
Share it on

Cancer Immunol Immunother. 2021 Oct;70(10):3055. doi: 10.1007/s00262-021-02977-6.

Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivo.

Cancer immunology, immunotherapy : CII

Anja Tatjana Teck, Sabrina Urban, Petra Quass, Annika Nelde, Heiko Schuster, Anne Letsch, Antonia Busse, Juliane Sarah Walz, Ulrich Keilholz, Sebastian Ochsenreither

Affiliations

  1. Department of Hematology and Oncology, Campus Benjamin Franklin, Charité Berlin, Berlin, Germany.
  2. Charité Comprehensive Cancer Center, Charitéplatz 1, 10117, Berlin, Germany.
  3. German Cancer Research Center (DKFZ), Heidelberg, Germany.
  4. Department of Immunology, Interfaculty Institute of Cell Biology, University of Tübingen, Tübingen, Germany.
  5. Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), University Hospital Tübingen, Tübingen, Germany.
  6. Immatics Biotechnologies GmbH, Tübingen, Germany.
  7. Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.
  8. Department of Hematology and Oncology, Campus Benjamin Franklin, Charité Berlin, Berlin, Germany. [email protected].
  9. Charité Comprehensive Cancer Center, Charitéplatz 1, 10117, Berlin, Germany. [email protected].
  10. German Cancer Research Center (DKFZ), Heidelberg, Germany. [email protected].

PMID: 34170381 PMCID: PMC8423697 DOI: 10.1007/s00262-021-02977-6

[No abstract available.]

Publication Types